Pharvaris NV Ordinary Shares PHVS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
-
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
-
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
-
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
-
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
-
Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
-
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
Trading Information
- Previous Close Price
- $29.64
- Day Range
- $27.68–29.54
- 52-Week Range
- $20.65–43.25
- Bid/Ask
- $25.12 / $30.00
- Shares Outstanding
- 70.20M
- Market Cap
- $1.95B
- Volume/Avg
- 1M / 734,661
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 129
- Website
- https://www.pharvaris.com
Valuation
|
Metric
|
PHVS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.67 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PHVS
|
|---|---|
Quick Ratio | 11.82 |
Current Ratio | 11.94 |
Interest Coverage | — |
Quick Ratio
PHVS
Profitability
|
Metric
|
PHVS
|
|---|---|
Return on Assets (Normalized) | −55.78% |
Return on Equity (Normalized) | −61.50% |
Return on Invested Capital (Normalized) | −63.60% |
Return on Assets
PHVS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!&vVkg | LOCK|yM?t | $127B | |||
| Moderna Inc
MRNA
| LOCK|z^Qfq% | LOCK|@NB | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#?!%^&q | LOCK|S^NRL | $81B | |||
| argenx SE ADR
ARGX
| LOCK|v?<N>v | LOCK|!WZ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%t#<Yk& | LOCK|&h< | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|S^y^<q | LOCK|#lRt | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|cW<#?pS | LOCK|hC&^ | $27B | |||
| Incyte Corp
INCY
| LOCK|Km%qwR& | LOCK|fQ% | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|M@?^n! | LOCK|?@ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<SLx&n | LOCK|ysT | $14B |
United States